LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Bristol-Myers Squibb Co.

Închisă

SectorSănătate

46.75 2.25

Rezumat

Modificarea prețului

24h

Curent

Minim

45.73

Maxim

46.79

Indicatori cheie

By Trading Economics

Venit

2.4B

2.5B

Vânzări

-1.1B

11B

P/E

Medie Sector

17.384

56.602

EPS

1.8

Randament dividend

5.15

Marjă de profit

21.98

Angajați

34,100

EBITDA

1.9B

4.5B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+22.79% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

5.15%

2.45%

Următoarele câștiguri

31 iul. 2025

Data viitoare de dividende

31 iul. 2025

Următoarea dată ex-dividende

4 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-17B

95B

Deschiderea anterioară

44.5

Închiderea anterioară

46.75

Sentimentul știrilor

By Acuity

45%

55%

157 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Bristol-Myers Squibb Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 11:32 UTC

Câștiguri

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

13 mai 2025, 16:48 UTC

Achiziții, Fuziuni, Preluări

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7 mai 2025, 20:09 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

2seventy Bio 1Q Rev $22.9M >TSVT

7 mai 2025, 20:08 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

2seventy Bio 1Q EPS 1c >TSVT

7 mai 2025, 20:08 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

7 mai 2025, 20:07 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

29 apr. 2025, 19:47 UTC

Câștiguri

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 apr. 2025, 15:22 UTC

Câștiguri

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 apr. 2025, 11:46 UTC

Câștiguri

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 apr. 2025, 11:42 UTC

Câștiguri

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 apr. 2025, 11:12 UTC

Câștiguri

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

28 apr. 2025, 21:15 UTC

Câștiguri

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 14:15 UTC

Top știri
Câștiguri

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 12:37 UTC

Market Talk
Câștiguri

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 apr. 2025, 11:17 UTC

Câștiguri

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 apr. 2025, 11:13 UTC

Top știri
Câștiguri

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 apr. 2025, 10:59 UTC

Câștiguri

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Comparație

Modificare preț

Bristol-Myers Squibb Co. Așteptări

Obiectiv de preț

By TipRanks

22.79% sus

Prognoză pe 12 luni

Medie 56.25 USD  22.79%

Maxim 68 USD

Minim 36 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

20 ratings

5

Cumpărare

14

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 50.57Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

157 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.